Clinical Trial Update: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations [Phase 3]

View source ↗

Summary

A Phase III open-label trial is evaluating first-line Dato-DXd in combination with Rilvegostomig for advanced non-squamous non-small cell lung cancer with high …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dato-DXd (datopotamab deruxtecan)
• Rilvegostomig (rilvegostomig)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: RECRUITING